BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, Feldstein AE. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology. 2012;56:1291-1299. [PMID: 22505276 DOI: 10.1002/hep.25778] [Cited by in Crossref: 100] [Cited by in F6Publishing: 88] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Morita M, Naito Y, Niki E, Yoshikawa T. Antioxidant action of fermented grain food supplement: Scavenging of peroxyl radicals and inhibition of plasma lipid oxidation induced by multiple oxidants. Food Chem 2017;237:574-80. [PMID: 28764037 DOI: 10.1016/j.foodchem.2017.05.157] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Niki E. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo evidence. Free Radic Biol Med. 2014;66:3-12. [PMID: 23557727 DOI: 10.1016/j.freeradbiomed.2013.03.022] [Cited by in Crossref: 268] [Cited by in F6Publishing: 182] [Article Influence: 33.5] [Reference Citation Analysis]
3 Li L, Li N, Pang W, Zhang X, Hammock BD, Ai D, Zhu Y. Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis. PLoS One 2014;9:e94092. [PMID: 24718617 DOI: 10.1371/journal.pone.0094092] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
4 An ZM, Dong XG, Guo Y, Zhou JL, Qin T. Effects and clinical significance of pentoxifylline on the oxidative stress of rats with diabetic nephropathy. J Huazhong Univ Sci Technolog Med Sci 2015;35:356-61. [PMID: 26072073 DOI: 10.1007/s11596-015-1437-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
5 Wenfeng Z, Yakun W, Di M, Jianping G, Chuanxin W, Chun H. Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease. Annals of Hepatology 2014;13:489-95. [DOI: 10.1016/s1665-2681(19)31247-5] [Cited by in Crossref: 58] [Article Influence: 8.3] [Reference Citation Analysis]
6 Sahini N, Borlak J. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Prog Lipid Res. 2014;54:86-112. [PMID: 24607340 DOI: 10.1016/j.plipres.2014.02.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
7 Liu H, Beier JI, Arteel GE, Ramsden CE, Feldstein AE, McClain CJ, Kirpich IA. Transient receptor potential vanilloid 1 gene deficiency ameliorates hepatic injury in a mouse model of chronic binge alcohol-induced alcoholic liver disease. Am J Pathol. 2015;185:43-54. [PMID: 25447051 DOI: 10.1016/j.ajpath.2014.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
8 Samala N, Tersey SA, Chalasani N, Anderson RM, Mirmira RG. Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. J Diabetes Complications 2017;31:1630-7. [PMID: 28886991 DOI: 10.1016/j.jdiacomp.2017.07.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
9 Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol. 2013;58:801-810. [PMID: 23183522 DOI: 10.1016/j.jhep.2012.11.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
10 Minicucci M, Oliveira F, Santos P, Polegato B, Roscani M, Fernandes AA, Lustosa B, Paiva S, Zornoff L, Azevedo P. Pentoxifylline Attenuates Cardiac Remodeling Induced by Tobacco Smoke Exposure. Arq Bras Cardiol 2016;106:396-403. [PMID: 27096523 DOI: 10.5935/abc.20160057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
11 Baran B, Akyüz F. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol 2014;20:14219-29. [PMID: 25339808 DOI: 10.3748/wjg.v20.i39.14219] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
12 Ashraf NU, Sheikh TA. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radic Res. 2015;49:1405-1418. [PMID: 26223319 DOI: 10.3109/10715762.2015.1078461] [Cited by in Crossref: 145] [Cited by in F6Publishing: 129] [Article Influence: 24.2] [Reference Citation Analysis]
13 Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23:7495-7504. [PMID: 29204050 DOI: 10.3748/wjg.v23.i42.7495] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
14 Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013;14:20704-20728. [PMID: 24132155 DOI: 10.3390/ijms141020704] [Cited by in Crossref: 189] [Cited by in F6Publishing: 177] [Article Influence: 23.6] [Reference Citation Analysis]
15 Sangouni AA, Ghavamzadeh S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr 2019;13:2917-22. [PMID: 31425956 DOI: 10.1016/j.dsx.2019.07.063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
16 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21:3777-3785. [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 62] [Article Influence: 13.2] [Reference Citation Analysis]
17 Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10:627-636. [PMID: 23958599 DOI: 10.1038/nrgastro.2013.149] [Cited by in Crossref: 335] [Cited by in F6Publishing: 302] [Article Influence: 41.9] [Reference Citation Analysis]
18 Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017;23:6549-70. [PMID: 29085205 DOI: 10.3748/wjg.v23.i36.6549] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 59] [Article Influence: 25.3] [Reference Citation Analysis]
19 Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:16841-16857. [PMID: 25492998 DOI: 10.3748/wjg.v20.i45.16841] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
20 Santoro N, Caprio S, Feldstein AE. Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. Clin Lipidol 2013;8:411-8. [PMID: 26405460 DOI: 10.2217/clp.13.39] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
21 Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240:809-820. [PMID: 25873078 DOI: 10.1177/1535370215579161] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
22 Lassailly G, Caiazzo R, Pattou F, Mathurin P. Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology. 2016;150:1835-1848. [PMID: 26971824 DOI: 10.1053/j.gastro.2016.03.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 10.2] [Reference Citation Analysis]
23 Michlin M, Argaev-Frenkel L, Weinstein-Fudim L, Ornoy A, Rosenzweig T. Maternal N-Acetyl Cysteine Intake Improved Glucose Tolerance in Obese Mice Offspring. Int J Mol Sci 2020;21:E1981. [PMID: 32183232 DOI: 10.3390/ijms21061981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591-638. [PMID: 24830559 DOI: 10.3390/ijms15058591] [Cited by in Crossref: 178] [Cited by in F6Publishing: 155] [Article Influence: 25.4] [Reference Citation Analysis]
25 Acedo SC, Caria CR, Gotardo ÉM, Pereira JA, Pedrazzoli J, Ribeiro ML, Gambero A. Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice. World J Hepatol 2015;7:2551-8. [PMID: 26523207 DOI: 10.4254/wjh.v7.i24.2551] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
26 Xue Y, Deng Q, Zhang Q, Ma Z, Chen B, Yu X, Peng H, Yao S, Liu J, Ye Y, Pan G. Gigantol ameliorates CCl4-induced liver injury via preventing activation of JNK/cPLA2/12-LOX inflammatory pathway. Sci Rep 2020;10:22265. [PMID: 33335297 DOI: 10.1038/s41598-020-79400-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res. 2014;164:312-322. [PMID: 25028077 DOI: 10.1016/j.trsl.2014.06.008] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
28 Polimeni L, Del Ben M, Baratta F, Perri L, Albanese F, Pastori D, Violi F, Angelico F. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol. 2015;7:1325-1336. [PMID: 26052378 DOI: 10.4254/wjh.v7.i10.1325] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 16.0] [Reference Citation Analysis]
29 Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:351-64. [PMID: 27063274 DOI: 10.1016/j.cld.2015.10.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
30 Puri P, Xu J, Vihervaara T, Katainen R, Ekroos K, Daita K, Min HK, Joyce A, Mirshahi F, Tsukamoto H, Sanyal AJ. Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese. J Lipid Res 2016;57:1017-28. [PMID: 27020313 DOI: 10.1194/jlr.M066175] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
31 Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37 Suppl 1:97-103. [PMID: 28052626 DOI: 10.1111/liv.13302] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 26.8] [Reference Citation Analysis]
32 Spengler EK, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc 2015;90:1233-46. [PMID: 26219858 DOI: 10.1016/j.mayocp.2015.06.013] [Cited by in Crossref: 127] [Cited by in F6Publishing: 102] [Article Influence: 21.2] [Reference Citation Analysis]
33 Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47:869-880. [PMID: 24004441 DOI: 10.3109/10715762.2013.837577] [Cited by in Crossref: 158] [Cited by in F6Publishing: 137] [Article Influence: 19.8] [Reference Citation Analysis]
34 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
35 Wu X, Yang J, Morisseau C, Robertson LW, Hammock B, Lehmler HJ. 3,3',4,4',5-Pentachlorobiphenyl (PCB 126) Decreases Hepatic and Systemic Ratios of Epoxide to Diol Metabolites of Unsaturated Fatty Acids in Male Rats. Toxicol Sci 2016;152:309-22. [PMID: 27208083 DOI: 10.1093/toxsci/kfw084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
36 Difonzo G, Pasqualone A, Silletti R, Cosmai L, Summo C, Paradiso VM, Caponio F. Use of olive leaf extract to reduce lipid oxidation of baked snacks. Food Res Int 2018;108:48-56. [PMID: 29735082 DOI: 10.1016/j.foodres.2018.03.034] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
37 Warner DR, Liu H, Ghosh Dastidar S, Warner JB, Prodhan MAI, Yin X, Zhang X, Feldstein AE, Gao B, Prough RA, McClain CJ, Kirpich IA. Ethanol and unsaturated dietary fat induce unique patterns of hepatic ω-6 and ω-3 PUFA oxylipins in a mouse model of alcoholic liver disease. PLoS One 2018;13:e0204119. [PMID: 30256818 DOI: 10.1371/journal.pone.0204119] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
38 Zhang CH, Zhou BG, Sheng JQ, Chen Y, Cao YQ, Chen C. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res 2020;159:104984. [PMID: 32502637 DOI: 10.1016/j.phrs.2020.104984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
39 Niki E. Oxidant-specific biomarkers of oxidative stress. Association with atherosclerosis and implication for antioxidant effects. Free Radical Biology and Medicine 2018;120:425-40. [DOI: 10.1016/j.freeradbiomed.2018.04.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
40 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
41 Houben T, Brandsma E, Walenbergh SMA, Hofker MH, Shiri-Sverdlov R. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis. Biochim Biophys Acta Mol Cell Biol Lipids 2017;1862:416-29. [PMID: 27472963 DOI: 10.1016/j.bbalip.2016.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wang Y, Kang Y, Qi C, Zhang T, Zhao H, Ji X, Yan W, Huang Y, Cui R, Zhang G, Shi G. Pentoxifylline enhances antioxidative capability and promotes mitochondrial biogenesis for improving age-related behavioral deficits. Aging (Albany NY) 2020;12:25487-504. [PMID: 33231568 DOI: 10.18632/aging.104155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
43 Zirnheld KH, Warner DR, Warner JB, Hardesty JE, Mcclain CJ, Kirpich IA. Dietary fatty acids and bioactive fatty acid metabolites in alcoholic liver disease. Liver Research 2019;3:206-17. [DOI: 10.1016/j.livres.2019.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
44 Ahadi S, Gharekhani A, Shiva A. Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. Arab Journal of Gastroenterology 2019;20:189-97. [DOI: 10.1016/j.ajg.2019.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Gawrieh S, Chalasani N. Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015;35:338-48. [PMID: 26378648 DOI: 10.1055/s-0035-1562951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
46 Munteanu MA, Mircea PA. From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome? Clujul Med 2014;87:80-6. [PMID: 26528002 DOI: 10.15386/cjmed-277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Pearlman M, Loomba R. State of the art: treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014;30:223-237. [PMID: 24717764 DOI: 10.1097/mog.0000000000000060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
48 Durazzo M, Belci P, Collo A, Grisoglio E, Bo S. Focus on therapeutic strategies of nonalcoholic Fatty liver disease. Int J Hepatol 2012;2012:464706. [PMID: 23209914 DOI: 10.1155/2012/464706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
49 Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180-190. [PMID: 27646933 DOI: 10.1136/gutjnl-2016-312431] [Cited by in Crossref: 214] [Cited by in F6Publishing: 199] [Article Influence: 42.8] [Reference Citation Analysis]
50 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013;10:676-85. [PMID: 24126564 DOI: 10.1038/nrgastro.2013.193] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
51 Corey KE, Rinella ME. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci 2016;61:1387-97. [PMID: 26942734 DOI: 10.1007/s10620-016-4083-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
52 Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014;20:5320-5330. [PMID: 24833862 DOI: 10.3748/wjg.v20.i18.5320] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 53] [Article Influence: 10.0] [Reference Citation Analysis]
53 Ohno T, Shimizu M, Shirakami Y, Miyazaki T, Ideta T, Kochi T, Kubota M, Sakai H, Tanaka T, Moriwaki H. Preventive effects of astaxanthin on diethylnitrosamine-induced liver tumorigenesis in C57/BL/KsJ-db/db obese mice. Hepatol Res 2016;46:E201-9. [PMID: 26147624 DOI: 10.1111/hepr.12550] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Podszun MC, Chung JY, Ylaya K, Kleiner DE, Hewitt SM, Rotman Y. 4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept. J Histochem Cytochem 2020;68:635-43. [PMID: 32867573 DOI: 10.1369/0022155420946402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
55 Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015;62:1417-1432. [PMID: 26189925 DOI: 10.1002/hep.27999] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 16.5] [Reference Citation Analysis]
56 Elnagdy M, Barve S, McClain C, Gobejishvili L. cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease. Biomolecules 2020;10:E1433. [PMID: 33050657 DOI: 10.3390/biom10101433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R, McIntyre TM, Feldstein AE, Hazen SL. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci 2014;59:1617-24. [PMID: 24464211 DOI: 10.1007/s10620-014-3031-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
58 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
59 Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol 2020;26:109-33. [PMID: 31969775 DOI: 10.3748/wjg.v26.i2.109] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
60 Loomba R, Quehenberger O, Armando A, Dennis EA. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. J Lipid Res. 2015;56:185-192. [PMID: 25404585 DOI: 10.1194/jlr.p055640] [Cited by in Crossref: 102] [Cited by in F6Publishing: 51] [Article Influence: 14.6] [Reference Citation Analysis]
61 Jonscher KR, Bruce KD. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Adv Exp Med Biol 2019;1134:33-58. [PMID: 30919331 DOI: 10.1007/978-3-030-12668-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Haus JM, Solomon TP, Kelly KR, Fealy CE, Kullman EL, Scelsi AR, Lu L, Pagadala MR, McCullough AJ, Flask CA. Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013;98:E1181-E1188. [PMID: 23616151 DOI: 10.1210/jc.2013-1229] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
63 Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2014;15:7352-7379. [PMID: 24786095 DOI: 10.3390/ijms15057352] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 11.3] [Reference Citation Analysis]
64 Warner DR, Liu H, Miller ME, Ramsden CE, Gao B, Feldstein AE, Schuster S, McClain CJ, Kirpich IA. Dietary Linoleic Acid and Its Oxidized Metabolites Exacerbate Liver Injury Caused by Ethanol via Induction of Hepatic Proinflammatory Response in Mice. Am J Pathol. 2017;187:2232-2245. [PMID: 28923202 DOI: 10.1016/j.ajpath.2017.06.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
65 Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease 2014;18:73-89. [DOI: 10.1016/j.cld.2013.09.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
66 Wen WX, Lee SY, Siang R, Koh RY. Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. Adv Ther 2017;34:1245-69. [PMID: 28484954 DOI: 10.1007/s12325-017-0547-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
67 Warner D, Vatsalya V, Zirnheld KH, Warner JB, Hardesty JE, Umhau JC, McClain CJ, Maddipati K, Kirpich IA. Linoleic Acid-Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol-Associated Liver Injury. Hepatol Commun 2021;5:947-60. [PMID: 34141982 DOI: 10.1002/hep4.1686] [Reference Citation Analysis]
68 Lee E, Lim Y, Kwon SW, Kwon O. Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. The Journal of Nutritional Biochemistry 2019;68:33-41. [DOI: 10.1016/j.jnutbio.2019.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
69 Gao B, Lang S, Duan Y, Wang Y, Shawcross DL, Louvet A, Mathurin P, Ho SB, Stärkel P, Schnabl B. Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. Dig Dis Sci 2019;64:1878-92. [PMID: 31076986 DOI: 10.1007/s10620-019-05638-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
70 Sunil VR, Vayas KN, Cervelli JA, Malaviya R, Hall L, Massa CB, Gow AJ, Laskin JD, Laskin DL. Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation. Exp Mol Pathol 2014;97:89-98. [PMID: 24886962 DOI: 10.1016/j.yexmp.2014.05.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
71 Niki E, Noguchi N. Antioxidant action of vitamin E in vivo as assessed from its reaction products with multiple biological oxidants. Free Radic Res 2021;:1-12. [PMID: 33327809 DOI: 10.1080/10715762.2020.1866181] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Luo WJ, Cheng TY, Wong KI, Fang WH, Liao KM, Hsieh YT, Su KY. Novel therapeutic drug identification and gene correlation for fatty liver disease using high-content screening: Proof of concept. Eur J Pharm Sci 2018;121:106-17. [PMID: 29800612 DOI: 10.1016/j.ejps.2018.05.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
73 Arcaro CA, Assis RP, Zanon NM, Paula-Gomes S, Navegantes LCC, Kettelhut IC, Brunetti IL, Baviera AM. Involvement of cAMP/EPAC/Akt signaling in the antiproteolytic effects of pentoxifylline on skeletal muscles of diabetic rats. J Appl Physiol (1985) 2018;124:704-16. [PMID: 29357512 DOI: 10.1152/japplphysiol.00499.2017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014;20:14172-14184. [PMID: 25339805 DOI: 10.3748/wjg.v20.i39.14172] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
75 Naudin CR, Maner-Smith K, Owens JA, Wynn GM, Robinson BS, Matthews JD, Reedy AR, Luo L, Wolfarth AA, Darby TM, Ortlund EA, Jones RM. Lactococcus lactis Subspecies cremoris Elicits Protection Against Metabolic Changes Induced by a Western-Style Diet. Gastroenterology. 2020;159:639-651.e5. [PMID: 32169430 DOI: 10.1053/j.gastro.2020.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
76 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
77 Fleet SE, Lefkowitch JH, Lavine JE. Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America 2017;46:217-31. [DOI: 10.1016/j.gtc.2017.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
78 Abd Al Haleem EN, Ibrahim FAM, Zaytoon SAB, Arafa HMM. Possible protective effect of TNF-α inhibition and triad NO/cGMP/VEGF activation on gastric ulcer in rats. Can J Physiol Pharmacol 2021;99:864-74. [PMID: 33400612 DOI: 10.1139/cjpp-2020-0725] [Reference Citation Analysis]
79 Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14. [DOI: 10.1111/apt.12543] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 8.1] [Reference Citation Analysis]
80 Ye JH, Chao J, Chang ML, Peng WH, Cheng HY, Liao JW, Pao LH. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Sci Rep 2016;6:33102. [PMID: 27612024 DOI: 10.1038/srep33102] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
81 Kuhn MJ, Mavangira V, Gandy JC, Zhang C, Jones AD, Sordillo LM. Differences in the Oxylipid Profiles of Bovine Milk and Plasma at Different Stages of Lactation. J Agric Food Chem 2017;65:4980-8. [PMID: 28570057 DOI: 10.1021/acs.jafc.7b01602] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
82 Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167-174. [PMID: 23973932 DOI: 10.1016/j.jhep.2013.07.042] [Cited by in Crossref: 154] [Cited by in F6Publishing: 131] [Article Influence: 19.3] [Reference Citation Analysis]
83 Ganguli S, DeLeeuw P, Satapathy SK. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. Hepat Med 2019;11:159-78. [PMID: 31814783 DOI: 10.2147/HMER.S188991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
84 Caligiuri SPB, Parikh M, Stamenkovic A, Pierce GN, Aukema HM. Dietary modulation of oxylipins in cardiovascular disease and aging. Am J Physiol Heart Circ Physiol 2017;313:H903-18. [PMID: 28801523 DOI: 10.1152/ajpheart.00201.2017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 10.5] [Reference Citation Analysis]
85 Yu Y, Cai J, She Z, Li H. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh). 2019;6:1801585. [PMID: 30828530 DOI: 10.1002/advs.201801585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
86 Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57. [PMID: 27501374 DOI: 10.1080/14728214.2016.1220533] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
87 Umeno A, Morita M, Yoshida Y, Naito Y, Niki E. Isomer distribution of hydroxyoctadecadienoates (HODE) and hydroxyeicosatetraenoates (HETE) produced in the plasma oxidation mediated by peroxyl radical, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen. Archives of Biochemistry and Biophysics 2017;635:96-101. [DOI: 10.1016/j.abb.2017.10.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
88 Woo Baidal JA, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Sci Transl Med 2016;8:323rv1. [PMID: 26819197 DOI: 10.1126/scitranslmed.aad8390] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 7.2] [Reference Citation Analysis]